Navigation Links
Study Shows Positron Emission Mammography (PEM) is Easy for Breast Imagers to Learn Regardless of Experience
Date:4/6/2011

SAN DIEGO, April 6, 2011 /PRNewswire/ -- The American Journal of Roentgenology published original research from two separate studies this month demonstrating continued clinical acceptance of  the Naviscan high-resolution breast PET scanner, otherwise known as a PEM scanner.  The first study concluded that breast radiologists can achieve a high level of diagnostic performance in interpreting PEM images after a 2-hour tutorial which can take months to achieve with MRI.  The second study established a standard lexicon for the evaluation of PEM images making it simple to share a diagnosis.

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment.  With increasing use of PEM imaging, there is a need for standardized terminology to describe findings seen on PEM, interpretation, and management recommendations, similar to the standardized classification that exists for other breast imaging modalities.  

The purpose of the interpretative skills study was to prospectively validate how easy it is to learn and standardize the interpretation of PEM by breast radiologists.  Thirty-six observers from 15 sites throughout the United States completed both PEM and MRI interpretive skills tasks.  All participants underwent a 2-hour training program for interpreting PEM images.  The median sensitivity and specificity for PEM assessment tasks were 100% and 83% respectively, compared to the median sensitively and specificity of MRI at 82% and 69% respectively. The results indicate that, with minimal training, experienced breast imagers showed high performance in interpreting PEM images.

"PEM interpretation is relatively simple," stated Dr. Priscilla Slanetz, Director of Breast Imaging Research and Education at Beth Israel Deaconess Medical Center, a participant in the study.  "Assessing for areas of focal uptake typically is straightforward and takes just 1-3 minutes at most. In comparison, interpreting breast MR can take anywhere between 5-20 minutes, depending upon the complexity of the case and the number of sequences acquired."

Complementing this study, the lexicon paper outlines a standardized terminology to report PEM findings, similar to the BI-RADS developed through the American College of Radiology used extensively for mammography, ultrasound, and breast MRI.  Twenty investigators reviewed 404 malignancies in 388 patients in the development of the PEM lexicon.  The most interesting finding was that category 3, "probably benign," had a substantially higher rate of malignancy when compared to other modalities demonstrating how PEM is more accurate and decisive at differentiating between malignant and benign lesions in what is called "specificity."  Ultimately, PEM's high specificity has been suggested to be able to reduce unnecessary biopsies.  

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Apple Rehab ... services, staged a mock evacuation of the facility as part of a disaster drill ... Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):